Pfizer-BioNTech's Covid-19 vaccine was 73% effective in protecting infants - aged 6 months to 4 years - during the period when the Omicron variant of the coronavirus was highly prevalent, the Pfizer pharmaceutical company announced Tuesday.
The US Food and Drug Administration (FDA) gave permission on 17 June to administer the vaccine to this age group.
The infants in the study received either three doses (3 μg) of the Pfizer-BioNTech vaccine or placebo. The efficacy of the vaccine was 73.2% in infants aged 6 months to 4 years, according to the results reported by the two pharmaceutical companies.
«While these results confirm that the three 3 µg doses of our Covid-19 vaccine provided infants with a high level of protection at a time when the Omicron BA.2 sub variant was highly prevalent, (...) we are also developing a bivalent anti-Omicron BA.4/BA.5 vaccine tailored to this age group to address these sub-variant variants,» said Ugur Shahin, CEO and co-founder of BioNTech.
